Nodular regenerative hyperplasia in a patient with generalized essential telangiectasia: Endotheliopathy as a causal factor
Sonja Rothweiler, Markus H. Heim, David Semela – 22 November 2013
Beyond liver fibrosis: Hepatic stellate cell senescence links obesity to liver cancer by way of the microbiome
Nicholas A. Shackel, Mathew A. Vadas, Jennifer R. Gamble, Geoffrey W. McCaughan – 22 November 2013
Hepatitis virus hijacks shuttle: Exosome‐like vesicles provide protection against neutralizing antibodies
Vedashree Ramakrishnaiah, Luc J.W. Laan – 22 November 2013
Nodular regenerative hyperplasia in a patient with generalized essential telangiectasia: Endotheliopathy as a causal factor
Sonja Rothweiler, Markus H. Heim, David Semela – 22 November 2013
Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis
Priya Handa, Bryan D. Maliken, James E. Nelson, Vicki Morgan‐Stevenson, Donald J. Messner, Barjinderjit K. Dhillon, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Clinton T. Elfers, Christian L. Roth, Kris V. Kowdley – 21 November 2013 – Obesity and adiponectin depletion have been associated with the occurrence of nonalcoholic fatty liver disease (NAFLD). The goal of this study was to identify the relationship between weight gain, adiponectin signaling, and development of nonalcoholic steatohepatitis (NASH) in an obese, diabetic mouse model.
Left‐liver hypertrophy after therapeutic right‐liver radioembolization is substantial but less than after portal vein embolization
Benjamin Garlipp, Thierry Baere, Robert Damm, Romy Irmscher, Mark Buskirk, Patrick Stübs, Frederic Deschamps, Frank Meyer, Ricarda Seidensticker, Konrad Mohnike, Maciej Pech, Holger Amthauer, Hans Lippert, Jens Ricke, Max Seidensticker – 21 November 2013 – In patients with liver malignancies potentially amenable to curative extended right hepatectomy but insufficient size of the future liver remnant (FLR), portal vein embolization (PVE) of the tumor‐bearing liver is used to induce contralateral liver hypertrophy but leaves the tumor untreated.
MicroRNA‐26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor‐cMet pathway
Xin Yang, Xiao‐Fei Zhang, Xu Lu, Hu‐Liang Jia, Lei Liang, Qiong‐Zhu Dong, Qing‐Hai Ye, Lun‐Xiu Qin – 21 November 2013 – MicroRNA (miR)‐26a can suppress tumor growth and metastasis of hepatocellular carcinoma (HCC). Since angiogenesis is important for tumor growth and metastasis, we investigated the possible roles of miR‐26a in tumor angiogenesis. Down‐regulation of miR‐26a was found to correlate with an increased angiogenic potential of HCC.
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)‐related cirrhosis aware of their HCV status improves survival: A modeling approach
Abbas Mourad, Sylvie Deuffic‐Burban, Nathalie Ganne‐Carrié, Thibaud Renaut‐Vantroys, Isabelle Rosa, Anne‐Marie Bouvier, Guy Launoy, Stephane Cattan, Alexandre Louvet, Sébastien Dharancy, Jean‐Claude Trinchet, Yazdan Yazdanpanah, Philippe Mathurin – 21 November 2013 – Because of the ongoing debate on the benefit of ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed the impact of screening on hepatitis C virus (HCV)‐related compensated cirrhosis patients aware of their HCV status.
Screening for liver cancer: Another piece of the puzzle?
Morris Sherman – 20 November 2013
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
Len Verbeke, Ricard Farre, Jonel Trebicka, Mina Komuta, Tania Roskams, Sabine Klein, Ingrid Vander Elst, Petra Windmolders, Tim Vanuytsel, Frederik Nevens, Wim Laleman – 20 November 2013 – The farnesoid X receptor (FXR) is a nuclear bile acid receptor involved in bile acid homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease.